Could GLP-1s become the next frontier in harm reduction? Clinical researchers have discovered that GLP‑1 drugs like Ozempic and Wegovy not only aid with diabetes and weight loss but may also reduce cravings and enhance satiation for alcohol, tobacco, cannabis, opioids, and possibly other addictive drugs like cocaine and methamphetamine. These exciting developments mean GLP-1s may soon become a new harm-reduction tool and possibly transform the treatment of substance use disorders. Our expert panel will explore the latest findings, their transformative implications for addiction treatment, and policies to improve affordability and access for those who need them.

Lunch to follow.

• “GLP‑1 for Addiction: the Medical Evidence for Opioid, Nicotine, and Alcohol Use Disorder,” by Nicholas Reville and Zarinah Agnew
• “The Breakthrough Drug to Conquer Addiction: Ozempic?,” by Maia Szalavitz
• “ It’s Time for Over-the-Counter Ozempic,” by Charles M. Silver, Jeffrey A. Singer, and Michael F. Cannon
• “GLP‑1 Agonists: A New Hope for Substance Use Disorders?,” by Jeffrey A. Singer
• “Drug Reformation: End Government’s Power to Require Prescriptions,” by Jeffrey A. Singer and Michael F. Cannon
• “RFK Jr. Says Drug Addicts Need Tough Love. Is He Right?,” by Sally Satel